

1 **Supplementary material**

2 ***Inclusion and exclusion criteria***

3 **Table S1 Inclusion and exclusion criteria**

Inclusion criteria	Exclusion criteria
<ul style="list-style-type: none"> • An Asthma Control Questionnaire (ACQ-6) Score >0.75 • Positive histamine challenge test (PC₂₀ <8 µg/mL, or <12 µg/mL and bronchodilator response ≥ 12%) • Worsening asthma symptoms with infection since last change in asthma therapy • Positive skin prick test to common aeroallergens (e.g. house dust mite, pollens, animal epithelia) • Treatment comprising inhaled corticosteroids (ICS) or combination inhaler (Long-Acting Beta Agonist with ICS) • Participant is willing for their GP to be informed of their participation • Absence of serum neutralizing antibodies to rhinovirus-A16 	<ul style="list-style-type: none"> • Presence of clinically significant diseases other than asthma (cardiovascular, renal, hepatic, gastrointestinal, haematological, pulmonary, neurological, genitourinary, autoimmune, endocrine, metabolic, neoplasia etc.), which, in the opinion of the investigator, may either put the patient at risk because of participation in the trial, or diseases which may influence the results of the study or the patient's ability to take part in it • Smoking history over past 12 months • Seasonal allergic rhinitis symptoms at screening or during the 3-week pre-treatment phase (prior to rhinovirus inoculation)